GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vascular Biogenics Ltd (NAS:VBLT) » Definitions » Price-to-Free-Cash-Flow

Vascular Biogenics (Vascular Biogenics) Price-to-Free-Cash-Flow : N/A (As of Apr. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Vascular Biogenics Price-to-Free-Cash-Flow?

As of today (2024-04-25), Vascular Biogenics's share price is $0.155. Vascular Biogenics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.23. Hence, Vascular Biogenics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Vascular Biogenics's Price-to-Free-Cash-Flow or its related term are showing as below:

VBLT's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.19
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Vascular Biogenics's Free Cash Flow per Share for the three months ended in Jun. 2023 was $-0.03. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.23.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -4.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 12.40% per year.

During the past 11 years, Vascular Biogenics's highest 3-Year average Free Cash Flow per Share Growth Rate was 46.40% per year. The lowest was -12.60% per year. And the median was 11.40% per year.


Vascular Biogenics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Vascular Biogenics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vascular Biogenics Price-to-Free-Cash-Flow Chart

Vascular Biogenics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vascular Biogenics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vascular Biogenics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Vascular Biogenics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vascular Biogenics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's Price-to-Free-Cash-Flow falls into.



Vascular Biogenics Price-to-Free-Cash-Flow Calculation

Vascular Biogenics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.155/-0.225
=N/A

Vascular Biogenics's Share Price of today is $0.155.
Vascular Biogenics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.23.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Vascular Biogenics  (NAS:VBLT) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Vascular Biogenics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Vascular Biogenics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Vascular Biogenics (Vascular Biogenics) Business Description

Traded in Other Exchanges
N/A
Address
8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Executives
Builders Vc Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
James Jimin Kim 10 percent owner C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404
B Capital Group Management, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Investors Ii Ltd. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Partners Ii, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Joseph P Wagner officer: Chief Scientific Officer 320 HATCH DRIVE, FOSTER CITY CA 94404
Tuomo Patsi director 320 HATCH DRIVE, FOSTER CITY NY 94404
Thomas Bock director, officer: Chief Executive Officer 320 HATCH DRIVE, FOSTER CITY NY 94404
Michele Galen director 320 HATCH DRIVE, FOSTER CITY CA 94404
Fr Capital Holdings, L.p. 10 percent owner 2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103
B Capital Fund Ii, L.p. 10 percent owner C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Builders Vc Fund I (canada), L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Builders Vc Entrepreneurs Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Dubin Thomas I H director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Peter Feinberg director C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142